Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.67 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.67 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | RPA1 | P27694 | 1/20 | 0.51 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943045 | 0.84 | SLC9A1 (0.62) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 | |
| SCHEMBL31686383 | 0.81 | NR4A1 (0.69) | NR4A1NR4A2NR4A3ALDH1A1HPGD | |
| SCHEMBL1313933 | 0.81 | NR4A1 (0.69) | NR4A1NR4A2NR4A3ALDH1A1HPGD | |
| SCHEMBL3741650 | 0.81 | SLC9A1 (0.67) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 | |
| SCHEMBL3005513 | 0.81 | NR4A1 (0.63) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 | |
| SCHEMBL3050183 | 0.80 | NR4A1 (1.00) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 | |
| SCHEMBL3061978 | 0.80 | NR4A1 (0.67) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 | |
| SCHEMBL4532675 | 0.80 | NR4A1 (0.67) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 | |
| SCHEMBL12877043 | 0.80 | SLC9A1 (0.51) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 | |
| SCHEMBL307282 | 0.80 | ALDH1A1 (0.92) | NR4A1NR4A2NR4A3SLC9A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| WO-2019175464-A1 | COMPOUNDS USEFUL AS INHIBITORS OF SODIUM-CALCIUM EXCHANGER (NCX) | ORION CORPORATION (FI) | 2019-09-19 | — | — | WO | disclosed |
| US-8748412-B2 | Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators | ARGUSINA BIOSCIENCE INC. (KY) | 2014-06-10 | — | — | US | disclosed |
| EP-2531198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | Argusina Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011097300-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004198-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | NR4A1 2007/4885NR4A2 2652/4885NR4A3 2311/4885 |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | PCNA, POLL, XPA | NR4A1 317/4885NR4A2 924/4885NR4A3 599/4885 |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | PCNA, POLL, DNA2 | NR4A1 284/4885NR4A2 877/4885NR4A3 579/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | NR4A1 4619/4885NR4A2 4337/4885NR4A3 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.